Pyrimidine derivatives with antitubercular activity.
Drug development
Mycobacterium tuberculosis
Pyrimidine
Structure-activity relationships
Tuberculosis
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Jan 2023
15 Jan 2023
Historique:
received:
27
10
2022
revised:
17
11
2022
accepted:
18
11
2022
pubmed:
3
12
2022
medline:
4
1
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
Small molecules with antitubercular activity containing the pyrimidine motif in their structure have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 and SPR720, have entered clinical trials. This review provides an overview of recent advances in the hit-to-lead drug discovery studies of antitubercular pyrimidine-containing compounds with the aim to highlight their structural diversity. In the first part, the review discusses the pyrimidine compounds according to their targets, pinpointing the structure-activity relationships of each pyrimidine family. The second part of this review is concentrated on antitubercular pyrimidine derivatives with a yet unexplored or speculative target, dividing the compounds according to their structural types.
Identifiants
pubmed: 36459759
pii: S0223-5234(22)00848-0
doi: 10.1016/j.ejmech.2022.114946
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Pyrimidines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114946Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.